Russo Andrea, Morescalchi Francesco, Donati Simone, Gambicorti Elena, Azzolini Claudio, Costagliola Ciro, Semeraro Francesco
Eye Clinic, Department of Neurological and Vision Sciences, University of Brescia, Piazzale Spedale Civili, 1, 25100, Brescia, Italy.
Department of Surgical and Morphological Sciences, University of Insurbia-Circolo Hospital, Varese, Italy.
Int Ophthalmol. 2018 Apr;38(2):855-867. doi: 10.1007/s10792-017-0489-3. Epub 2017 Mar 13.
Proliferative vitreoretinopathy in the inferior retina remains clinically challenging. Heavier-than-water intraocular tamponades have been developed to improve inferior tamponading properties, and their chemical compositions have been substantially improved over the years, in parallel with developments in vitrectomy instrumentation and surgical techniques. Herein we present an updated review of the clinical use of standard formulations and HSO, focusing on analysis of the intraocular inflammation associated with endotamponade agents, and comparison of the adverse effects of these agents on the physical and biological properties of the eye.
A detailed literature search was conducted on PubMed, EMBASE, Cochrane Library, and Google Scholar using the key words. Fifty-eight articles matched our inclusion criteria that were included in this systematic review.
Perfluorocarbon liquids and partially fluorinated alkanes are associated with tamponade emulsification, intraocular inflammation, and rises in intraocular pressure, but these associations are not as strong when these substances are mixed with a heavy silicone oil (HSO). Two recently approved heavy silicone oil tamponades, Oxane HD and Densiron 68, are now available for use in clinical practice. While the complication spectrum of the new generation of these HSOs seems to be similar to that of conventional silicone oil tamponades, they provide better support for the inferior retina and the posterior pole.
Both regular and heavy silicone oils usually yield good success rates in cases of complicated retinal detachment. Decisions as to whether to utilize heavy or regular silicone oil should be made on a case-by-case basis.
视网膜下方的增殖性玻璃体视网膜病变在临床上仍然具有挑战性。已开发出比重比水大的眼内填塞物以改善下方填塞性能，并且随着玻璃体切割器械和手术技术的发展，其化学成分多年来已得到大幅改进。在此，我们对标准配方和重硅油（HSO）的临床应用进行了更新综述，重点分析与眼内填塞剂相关的眼内炎症，并比较这些药物对眼睛物理和生物学特性的不良反应。
使用关键词在PubMed、EMBASE、Cochrane图书馆和谷歌学术上进行了详细的文献检索。58篇符合我们纳入标准的文章被纳入本系统综述。
全氟碳液体和部分氟化烷烃与填塞物乳化、眼内炎症和眼压升高有关，但当这些物质与重硅油（HSO）混合时，这些关联并不那么强烈。两种最近批准的重硅油填塞物，Oxane HD和Densiron 68，现已可用于临床实践。虽然新一代重硅油的并发症谱似乎与传统硅油填塞物相似，但它们为视网膜下方和后极提供了更好的支撑。
在复杂性视网膜脱离病例中，普通硅油和重硅油通常都能取得较好的成功率。应根据具体情况决定是否使用重硅油或普通硅油。
